Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN
2019
BackgroundWe assessed the safety profile of lasmiditan, a selective 5-HT1F receptor agonist without vasoconstrictive activity being developed as an acute therapy for migraine.MethodsSAMURAI and SPA...
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
15
References
31
Citations
NaN
KQI